P1‐112: Effects of 12 months of treatment with the PPARγ agonist rosiglitazone on brain glucose metabolism in Alzheimer's Disease: A <sup>18</sup>F‐FDG PET study
Eugenii A. Rabiner(GlaxoSmithKline (United Kingdom)), Paul M. Matthews(Rosalind Franklin Institute), Julian C. Matthews(Manchester Academic Health Science Centre), Brandon Whitcher(Royal Marsden NHS Foundation Trust), Mike Gold, Narinder Lotay(GlaxoSmithKline (United Kingdom)), Eric M. Reiman(Alzheimer's Association), Marina Zvartau‐Hind(GlaxoSmithKline (United Kingdom)), Sofia Tzimopoulou(GlaxoSmithKline (United Kingdom)), Nick Bird(GlaxoSmithKline (United Kingdom)), Thomas E. Nichols(University of Oxford), Mary Castiglia(Research Triangle Park Foundation), Barbara Jeter(Research Triangle Park Foundation), Kewei Chen(Good Samaritan Medical Center), Vincent J. Cunningham(GlaxoSmithKline (United Kingdom)), Ann M. Saunders(St George's, University of London), Robert Lai(Eisai (United Kingdom)), Praful Mistry(GlaxoSmithKline (United Kingdom))
Cited by 3
Related Papers
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data
|NeuroImage|2006|6.6k
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
|Neurology|1993|3.8k
A Resilient, Low-Frequency, Small-World Human Brain Functional Network with Highly Connected Association Cortical Hubs
|Journal of Neuroscience|2006|2.5k
Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging
|Nature Neuroscience|2003|2.4k